Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 12:19 pm Sale | 2025-09-30 | 13G | Monte Rosa Therapeutics, Inc. GLUE | T. Rowe Price Associates, Inc. | 4,637,060 7.500% | -1,964,081 (-29.75%) | Filing History |
| 2025-11-14 09:07 am Sale | 2025-09-30 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 0 0.000% | -3,725,000 (Position Closed) | Filing History |
| 2025-11-12 4:13 pm Sale | 2025-11-10 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 3,334,669 5.100% | -744,800 (-18.26%) | Filing History |
| 2025-10-31 11:04 am Sale | 2025-09-30 | 13G | Monte Rosa Therapeutics, Inc. GLUE | The Vanguard Group | 2,988,953 4.830% | -167,401 (-5.30%) | Filing History |
| 2025-10-17 4:29 pm Purchase | 2025-10-10 | 13G | Monte Rosa Therapeutics, Inc. GLUE | TCG Crossover GP II, LLC | 4,427,705 7.200% | 4,427,705 (New Position) | Filing History |
| 2025-10-03 12:19 pm Purchase | 2024-05-16 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Adam Goulburn | 4,757,563 7.700% | 4,757,563 (New Position) | Filing History |
| 2025-08-14 07:10 am Sale | 2025-06-30 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 3,725,000 6.100% | -620,000 (-14.27%) | Filing History |
| 2025-06-06 10:03 am Sale | 2025-05-30 | 13G | Monte Rosa Therapeutics, Inc. GLUE | FMR LLC | 1,750,731 2.800% | -3,350,682 (-65.68%) | Filing History |
| 2025-05-15 4:33 pm Purchase | 2025-03-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BIOTECHNOLOGY VALUE FUND L P | 5,660,132 9.200% | 1,266,922 (+28.84%) | Filing History |
| 2025-04-16 5:30 pm Purchase | 2025-04-09 | 13G | Monte Rosa Therapeutics, Inc. GLUE | SUVRETTA CAPITAL MANAGEMENT LLC | 3,360,000 5.500% | 3,360,000 (New Position) | Filing History |
| 2025-02-14 09:30 am Sale | 2024-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 4,345,000 7.100% | -190,000 (-4.19%) | Filing History |
| 2025-02-04 3:45 pm Purchase | 2024-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BlackRock Inc. BLK | 3,840,165 6.300% | 1,468,185 (+61.90%) | Filing History |
| 2025-01-31 6:43 pm Purchase | 2025-01-24 | 13G | Monte Rosa Therapeutics, Inc. GLUE | BIOTECHNOLOGY VALUE FUND L P | 4,393,210 7.200% | 4,393,210 (New Position) | Filing History |
| 2025-01-30 9:58 pm Purchase | 2024-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | The Vanguard Group | 3,156,354 5.130% | 3,156,354 (New Position) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Monte Rosa Therapeutics, Inc. GLUE | T. Rowe Price Associates, Inc. | 6,601,141 10.800% | 1,504,354 (+29.52%) | Filing History |
| 2024-11-12 10:32 am Sale | 2024-11-08 | 13G | Monte Rosa Therapeutics, Inc. GLUE | FMR LLC | 5,101,413 8.312% | -435,826 (-7.87%) | Filing History |
| 2024-10-30 5:10 pm Sale | 2024-10-28 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 4,079,469 6.600% | -1,019,867 (-20.00%) | Filing History |
| 2024-09-24 5:00 pm Sale | 2024-09-20 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 5,099,336 8.300% | -1,699,779 (-25.00%) | Filing History |
| 2024-08-12 7:46 pm Sale | 2024-08-08 | 13D | Monte Rosa Therapeutics, Inc. GLUE | New Enterprise Associates 17, L.P. | 7,774,930 12.700% | -10,000 (-0.13%) | Filing History |
| 2024-08-12 5:07 pm Unchanged | 2024-08-08 | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI, L.P. | 6,799,115 11.100% | 0 (Unchanged) | Filing History |